Search Results

Scope 1, 2 and 3 historic/comparative carbon emissions (tCO2e) from 2021 to 2024, noting the increase in total emissions this reporting year due to the inclusion of all Scope 3 category data.

CSL commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY 2030 (from a FY 2021 base year).

In fiscal year 2021-2022, CSL invested approximately $1.16 billion in R&D.

CSL was originally established by the Australian government in As at 30 June 2021, the CSL Group employed over 25,000 full 1916 for the purpose of supplying Australia with vaccines and time equivalents (FTE) and delivered medicines to patients other bacteriological products.

NEDs Dr Brian McNamee AO Chair and Independent Non-Executive Director Full year Dr Megan Clark AC Independent Non-Executive Director Full year Professor Andrew Cuthbertson AO Independent Non-Executive Director Full year Dr Brian Daniels Independent Non-Executive Director Part year - from 1 December 2024 Ms Carolyn Hewson AO Independent Non-Executive Director Full year Ms Samantha Lewis Independent Non-Executive Director Full year Ms Marie McDonald Independent Non-Executive Director Full year Ms Elaine Sorg Independent Non-Executive Director Part year - from 1 September 2024 Ms Alison Watkins AM Independent Non-Executive Director Full year

CSL’s vision is a sustainable future for our employees, communities, patients and donors, inspired by innovative science and a values-driven culture.

CSL’s Code of Conduct (the Code) sets the standards for how we conduct business in an ethical and transparent way through our commitment to governance and compliance with all applicable laws, regulations and industry standards.

N Engl J Med 2021

CSL engages stakeholders and periodically undertakes a formal materiality assessment process to understand our relevant sustainability-related topics.

IgA Nephropathy/IgA Vasculitis from the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases .